Information Provided By: 
Fly News Breaks for February 27, 2020
ESPR
Feb 27, 2020 | 14:20 EDT
JMP Securities analyst Jason Butler reiterates an Outperform rating on Esperion Therapeutics with a $191 price target after the company received a second FDA approval in a week for its bempedoic acid franchise. Nexlizet and Nexletol will be priced at parity at $10 per day WAC, and conversations with payers to-date have included both, Butler tells investors in a research note. Over the long term, the analyst sees an "obvious cost benefit" of the fixed-dose combination to patients with only a single copay.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
